ArticleJournal of personalized medicine2023
Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer.
Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.Cancer medicine · 2025Pooled it
- Dynamic Profiling of Circulating Tumor Cells and MYC/PTEN Alterations in Prostate Cancer Patients Undergoing Radical Prostatectomy in Amazon Population.Molecular carcinogenesis · 2026Article
- Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer.The British journal of radiology · 2025Review
- Liquid biopsy of circulating tumor cells: From isolation, enrichment, and genome sequencing to clinical applications.Histology and histopathology · 2025Review
- A narrative review of the current state of circulating tumor cells in prostate cancer diagnostic.Hellenic urology · 2025Article
- Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy.Diagnostics (Basel, Switzerland) · 2024Article
- Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients.Cellular and molecular life sciences : CMLS · 2024Article
- Prognostic evaluation of a multi-target magnetic bead-enriched circulating tumor cell-enriched identification system for colorectal cancer.Journal of gastrointestinal oncology · 2024Article
- Clinical application of circulating tumor cells.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.